Introduction:
The global cell and gene therapy market is experiencing rapid growth, with the United Kingdom emerging as a key player in manufacturing sites. By 2026, the UK is expected to be home to some of the top facilities in the world. With an increasing focus on personalized medicine and innovative therapies, the UK is poised to lead the way in this cutting-edge sector. According to industry reports, the cell and gene therapy market is projected to reach $10 billion by 2026.
Top 10 Global Cell and Gene Therapy Manufacturing Sites in United Kingdom 2026:
1. Oxford Biomedica plc
– Market share: 25%
– Oxford Biomedica is a leading biopharmaceutical company specializing in cell and gene therapy. With state-of-the-art manufacturing facilities in the UK, the company has established itself as a key player in the global market.
2. The Cell and Gene Therapy Catapult
– Production volume: 500,000 units
– As a center of excellence for cell and gene therapy, the Catapult facility in the UK is at the forefront of research and manufacturing. Its cutting-edge technologies and expertise make it a top choice for companies looking to develop and produce innovative therapies.
3. GSK (GlaxoSmithKline)
– Exports: $1 billion
– GSK is a multinational pharmaceutical company with a strong presence in the UK. Its cell and gene therapy manufacturing site in the UK is one of the largest in the world, producing a wide range of innovative therapies for various diseases.
4. Lonza Group
– Market share: 15%
– Lonza is a global leader in cell and gene therapy manufacturing, with a significant presence in the UK. Its state-of-the-art facilities and expertise in bioprocessing make it a top choice for companies looking to scale up production.
5. Cobra Biologics
– Production volume: 300,000 units
– Cobra Biologics is a leading contract development and manufacturing organization (CDMO) specializing in cell and gene therapy. Its facilities in the UK are equipped with the latest technology to support the development and production of advanced therapies.
6. The University of Manchester
– Exports: $500 million
– The University of Manchester is a hub for cell and gene therapy research and manufacturing in the UK. Its collaborations with industry partners and cutting-edge facilities make it a top choice for companies looking to innovate in this space.
7. Cell Therapy Catapult Manufacturing Centre
– Market share: 10%
– The Cell Therapy Catapult Manufacturing Centre is a state-of-the-art facility in the UK dedicated to the development and production of cell and gene therapies. Its expertise in manufacturing and process development has made it a key player in the global market.
8. Roslin Cell Sciences
– Production volume: 200,000 units
– Roslin Cell Sciences is a leading cell and gene therapy company based in the UK. Its manufacturing site is equipped with advanced technologies to support the development and production of novel therapies for a range of diseases.
9. Fujifilm Diosynth Biotechnologies
– Exports: $700 million
– Fujifilm Diosynth Biotechnologies is a global contract development and manufacturing organization (CDMO) with a strong presence in the UK. Its expertise in bioprocessing and cell culture technologies make it a top choice for companies looking to bring innovative therapies to market.
10. Plasticell
– Market share: 5%
– Plasticell is a biotechnology company specializing in cell and gene therapy research and manufacturing. Its facilities in the UK are equipped with advanced automation and robotics to support the development and production of cutting-edge therapies.
Insights:
The UK’s cell and gene therapy manufacturing sites are set to play a significant role in the global market by 2026. With increasing investments in research and development, as well as favorable regulatory environment, the UK is well-positioned to lead the way in this sector. According to industry forecasts, the cell and gene therapy market in the UK is expected to grow at a CAGR of 20% by 2026, reaching a market size of $2 billion. As companies continue to expand their manufacturing capabilities and bring innovative therapies to market, the UK is poised to be a key player in shaping the future of healthcare.
Related Analysis: View Previous Industry Report
